A cyclometallated iridium(III) complex with multi-photon absorption properties as an imaging-guided photosensitizer

J Mater Chem B. 2022 Aug 4;10(30):5765-5773. doi: 10.1039/d2tb01023b.

Abstract

Conventional photosensitizers (PSs) often have shorter excitation wavelengths and poor cancer cell targeting, resulting in a limited tissue penetration depth and increased biotoxicity, which are significant barriers to ensuring effective photodynamic therapy (PDT) in vivo. In this work, a cyclometallated iridium(III) complex (Ir-Biotin) with a long excitation wavelength and effective cancer cell targeting was designed and synthesized. The initial in vitro assessment indicated that Ir-Biotin shows excellent PDT activity with a high singlet-oxygen (1O2) generation yield (0.19) due to the facilitated intersystem crossing process. Further study shows that Ir-Biotin shows good biocompatibility, has specific selectivity for cancer cells, and can induce apoptosis under laser irradiation. Furthermore, Ir-Biotin can be applied for imaging-guided PDT using an in vivo imaging system, and showed significant anti-tumour effects (tumour growth inhibition value: 87.66%). These results reveal the importance of long excitation wavelengths of photosensitizers for efficient PDT and suggest a promising strategy for developing effective photosensitizers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biotin
  • Humans
  • Iridium / pharmacology
  • Neoplasms* / drug therapy
  • Photochemotherapy* / methods
  • Photosensitizing Agents / pharmacology
  • Photosensitizing Agents / therapeutic use
  • Singlet Oxygen

Substances

  • Photosensitizing Agents
  • Singlet Oxygen
  • Iridium
  • Biotin